Jaume Puig-Junoy1. 1. Centro de Investigación en Economía y Salud, Departamento de Economía y Empresa, Universitat Pompeu Fabra, Barcelona, España. jaume.puig@upf.edu
Abstract
OBJECTIVES: To describe alternative policies aimed at encouraging price competition in generic drug markets in countries with strict price regulation, and to present some case studies drawn from the European experience. METHODS: Systematic literature review of articles and technical reports published after 1999. RESULTS: The shortcomings in consumer price competition observed in some European generic markets, including Spain, may be reduced through three types of public reimbursement or financing reforms: policies aimed at improving the design of current maximum reimbursement level policies; policies aimed at monitoring competitive prices in order to reimburse real acquisition cost to pharmacies; and, more radical and market-oriented policies such as competitive tendering of public drug purchases. The experience of recent reforms adopted in Germany, Belgium, Holland, Norway, and Sweden offers a useful guide for highly price-regulated European countries, such as Spain, currently characterized by limited consumer price competition and the high discounts offered to pharmacy purchases. CONCLUSIONS: Direct price regulation and/or the generic reference pricing systems used to reduce generic drug prices in many European countries can be successfully reformed by adopting measures more closely aimed at encouraging consumer price competition in generic drug markets. Copyright 2009 SESPAS. Published by Elsevier Espana. All rights reserved.
OBJECTIVES: To describe alternative policies aimed at encouraging price competition in generic drug markets in countries with strict price regulation, and to present some case studies drawn from the European experience. METHODS: Systematic literature review of articles and technical reports published after 1999. RESULTS: The shortcomings in consumer price competition observed in some European generic markets, including Spain, may be reduced through three types of public reimbursement or financing reforms: policies aimed at improving the design of current maximum reimbursement level policies; policies aimed at monitoring competitive prices in order to reimburse real acquisition cost to pharmacies; and, more radical and market-oriented policies such as competitive tendering of public drug purchases. The experience of recent reforms adopted in Germany, Belgium, Holland, Norway, and Sweden offers a useful guide for highly price-regulated European countries, such as Spain, currently characterized by limited consumer price competition and the high discounts offered to pharmacy purchases. CONCLUSIONS: Direct price regulation and/or the generic reference pricing systems used to reduce generic drug prices in many European countries can be successfully reformed by adopting measures more closely aimed at encouraging consumer price competition in generic drug markets. Copyright 2009 SESPAS. Published by Elsevier Espana. All rights reserved.
Authors: Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson Journal: Pharmaceuticals (Basel) Date: 2010-08-05